Status:

COMPLETED

Effects of Lubiprostone on Small Bowel and Colonic Bacteria: A Correlation Study With Segmental and Whole Gut Transit

Lead Sponsor:

University of Louisville

Collaborating Sponsors:

Takeda

Conditions:

Constipation

Eligibility:

All Genders

18-65 years

Phase:

PHASE4

Brief Summary

Patients with constipation often have bloating and abdominal distension. It is unclear if this is related to intestinal bacteria. Hypothesis: treatment for constipation may reduce small bowel and colo...

Detailed Description

This is an open-label study to collect data on upper and lower GI symptoms, hydrogen breath test, stool PCR, and serum before and after 4 weeks of lubiprostone 24 mcg by mouth twice a day for 4 weeks.

Eligibility Criteria

Inclusion

  • Functional constipation by Rome III criteria

Exclusion

  • History of esophageal or gastric surgery (including vagotomy, antireflux, and obesity surgery)
  • History of small bowel or colon resection (excluding appendectomy and cholecystectomy)
  • History of gastric outlet, small bowel, or colon obstruction
  • History of surgery for small bowel adhesion lysis
  • History of surgery for gastroparesis
  • Diagnosis of diabetes requiring daily medications
  • Diagnosis of connective tissue d/o (including scleroderma, lupus, mixed connective tissue disorder)
  • Diagnosis of neuromuscular disorder (including multiple sclerosis, Parkinson, muscular dystrophy, dysautonomia, dystonia)
  • Disorders of small bowel pseudo-obstruction or dumping syndrome
  • Untreated or poorly controlled hypothyroidism
  • Taking an opiate medication daily
  • Taking a medication daily that can cause constipation (calcium channel blocker, anticholinergic, iron supplements, etc.)
  • Active cancer being treated
  • History of significant liver, kidney, cardiac disease that may interfere with study compliance
  • Known allergy or side effects to lubiprostone
  • Non-ambulatory patients: bed-ridden, nursing home resident, etc.

Key Trial Info

Start Date :

May 1 2009

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

May 1 2011

Estimated Enrollment :

25 Patients enrolled

Trial Details

Trial ID

NCT00844831

Start Date

May 1 2009

End Date

May 1 2011

Last Update

July 27 2017

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University of Louisville

Louisville, Kentucky, United States, 40202

Effects of Lubiprostone on Small Bowel and Colonic Bacteria: A Correlation Study With Segmental and Whole Gut Transit | DecenTrialz